ERBB2 and breast carcinoma: A total of 13 studies were included in this meta-analysis, comprising 5 RCTs and 8 single-arm studies, enrolling a total of 2,447 patients with mTNBC or HR+/HER2- mBC or early-stage breast cancer patients.